Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華領醫藥

(Incorporated in the Cayman Islands with limited liability)

(: 2552)

This announcement is made by Hua Medicine (the "**C** ") together with its subsidiaries the "") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**B** ") of directors (the " ") of the Company wishes to inform the shareholders of the Company (the " ") and potential investors that, based on the preliminary assessment of the unaudited management accounts of the Group for the six months ended June 30, 2025 (the "**G** ") and information currently available to the Group, the Group expects to record a profit of approximately RMB1,184.1 million for the Current Reporting Period as compared with a loss for the period of approximately RMB142.0 million for the corresponding period in 2024.

Reference is made to (i) the "Important events after the Reporting Period" of the 2024 annual report of the Company published 24 April 2025 (the "**2024 A** ") which stated that upon the termination of the exclusive promotion service agreement with Bayer on January 1, 2025, the unamortized contract liabilities amounting to RMB1,243.5 million were released to profit or loss, and recognized as a gain by the Group and (ii) the second item under "Business and financial highlights" of the 2024 Annual Report which stated that the Company assumed full responsibility for commercialization of HuaTangNing (华堂宁®) in mainland China. In this respect, the Company recruited a pharmaceutical sales executive with over 20 years of diabetes commercialization experience in China to lead our sales and marketing efforts.

In addition to the recognition of the remaining unamortized contract liabilities associated with the now terminated exclusive promotion service agreement with Bayer noted above, the expected improvement in profitability is due to the successful transition of commercialization responsibility for HuaTangNing (华堂宁®) in China and the increase in manufacturing efficiencies leading